Panacea Biotec shares experienced a remarkable 60% surge over six trading days, reaching a new high of ₹637.70 on Tuesday's intra-day trade. According to reports from Business Standard, the stock price had touched ₹398.45 on June 1, 2026, demonstrating the dramatic upward momentum. The pharmaceutical company's shares have skyrocketed 101% in the past two months, significantly outperforming broader market indices. At 12:07 PM on Tuesday, the stock was trading 13% higher at ₹625.95, compared to a 0.20% rise in the BSE Sensex, as reported by Business Standard.
On Monday, June 8, 2026, Panacea Biotec announced the launch of the DENSTAR (Dengue Efficacy and Safety Trial in African Region) project, aimed at advancing the regulatory approval and global access of its dengue vaccine candidate, DengiAll. As reported by Business Standard, the four-year initiative is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU), supported by the European Union and aligns with the EDCTP3 mission to combat Neglected Tropical Diseases including dengue fever. The project is coordinated by the Sclavo Vaccines Association, a non-profit organization based in Siena, Italy, and unites 10 partners from 9 countries across Europe, Africa, the United States, India and South Korea.
According to Business Standard, the average trading volumes at the counter jumped over five-fold, with a combined 9.95 million shares representing 16% of total equity of the company changing hands on the NSE and BSE. The heavy trading volumes accompanied the stock's surge, indicating strong investor interest in the dengue vaccine project announcement. The company has also received higher long-term business orders for vaccines from key institutional customers, as reported by Business Standard.
For the financial year ended March 31, 2026, Panacea Biotec and group incurred losses of ₹28.74 crore and ₹1.74 crore respectively, compared to losses of ₹15.18 crore and ₹7.61 crore in the previous year, as reported by Business Standard. The company's retained earnings are negative to the extent of ₹217.82 crore as of March 31, 2026, indicating uncertainty about its ability to continue as a going concern. However, the group's retained earnings remain positive at ₹776.05 crore, with surplus funds from pharmaceutical formulations sales helping strengthen working capital position and fund vaccine manufacturing capacity expansion.
According to Business Standard, Panacea Biotec is one of the leading manufacturers of paediatric vaccines and played a pivotal role in eradicating poliomyelitis from India and other countries, being one of the largest suppliers of oral polio vaccines to UNICEF, the Government of India and other developing countries. The company has supplied more than 10 billion doses of polio vaccine in India and developing countries and more than 200 million immunizations by supplying fully liquid wP based combination vaccines over the last two decades.
